Human Milk Oligosaccharides (HMO) Market Set for Rapid Growth to US$ 1,386.9 Million by 2033, Driven by North America's 34.5% Market Share

DataM Intelligence has released a new research report titled "Human Milk Oligosaccharides (HMO) Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Human Milk Oligosaccharides (HMO) Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/human-milk-oligosaccharides-market?ram

The Global Human Milk Oligosaccharides (HMO) Market reached USD 320.4 million in 2025 and is projected to reach USD 1,386.9 million by 2033, growing at a CAGR of 20.1% during the forecast period 2026-2033.

The market is experiencing significant growth due to the increasing demand for infant nutrition products that closely mimic the functional benefits of human breast milk. Rising awareness regarding infant gut health, immunity development, and cognitive support is encouraging manufacturers to incorporate HMOs into premium infant formula, dietary supplements, and functional nutrition products.

Industry participants are increasingly focusing on advanced microbial fermentation technologies and strategic collaborations to expand large-scale HMO production capabilities and improve product accessibility worldwide. Growing investments in clinical research, regulatory approvals for novel HMO ingredients, and expanding applications in adult nutrition, medical nutrition, and microbiome health are further strengthening the long-term commercial potential of the market.

Key Industry Developments

United States:
✅ March 2026: dsm-firmenich expanded its Human Milk Oligosaccharides (HMO) portfolio with new regulatory approvals across Asia, including commercialization of its 3'-SL ingredient for early-life nutrition applications. The development strengthened the company's HMO innovation pipeline and reinforced its position in advanced infant nutrition solutions for global formula manufacturers.

✅ February 2026: dsm-firmenich highlighted technological advancements in precision-fermentation-based HMO production, supporting scalable manufacturing of ingredients such as 2'-FL, LNnT, and 3'-SL for infant nutrition. The company emphasized enhanced formulation capabilities aimed at improving gut health, immune support, and cognitive development in infants.

✅ November 2025: Abbott Laboratories continued expanding premium infant nutrition formulations in the U.S. with increased incorporation of HMOs and microbiome-supporting ingredients in pediatric products. The company focused on science-backed nutritional innovations designed to mimic key functional benefits of human breast milk.

Japan:
✅ March 2026: Morinaga Milk Industry advanced research initiatives focused on combining probiotics with Human Milk Oligosaccharides (HMOs) to enhance infant gut microbiome development and digestive health. The company continued strengthening its infant nutrition R&D strategy centered on HMO-compatible probiotic strains and next-generation functional nutrition.

✅ December 2025: Morinaga Milk Industry expanded international commercialization activities for its functional nutrition portfolio, including probiotic technologies designed for HMO-based infant nutrition applications.

Strategic Acquisitions & Partnerships
✅ Roquette Ventures - Strategic Investment / Partnership
(March, 2026)
Roquette Ventures announced an investment in Advanced Protein Technologies (AP Technologies), a South Korean biotechnology company developing human milk oligosaccharide (HMO) technologies. The partnership is intended to accelerate commercialization of HMO ingredients for food and pharmaceutical applications while expanding AP Technologies' international growth capabilities.

✅ BENEO GmbH - Strategic Partnership
(May, 2025)
BENEO and WACKER officially announced a partnership focused on the commercialization and distribution of human milk oligosaccharides for the infant nutrition and functional food sectors. Under the agreement, WACKER supplies fermentation-derived HMOs while BENEO manages global commercialization using its established nutrition ingredient network.

Key Players:
Elicityl SA | Medolac Laboratories | Inbiose NV | Glycosyn | ZuChem | Jennewein Biotechnologie GmbH | Glycom A/S | Dextra Laboratories Limited | DuPont Nutrition & Health | Nestlé Health Science

Strategic Leadership Analysis: Top 5 Key Players in Human Milk Oligosaccharides (HMO) Market 2026
Glycom A/S: Expanded its advanced HMO ingredient portfolio through regulatory approvals across Australia, New Zealand, and Asia-Pacific markets, strengthening the commercialization of infant nutrition solutions. Recently supported the launch and approval expansion of GlyCareTM HMO ingredients including 2'-FL/DFL, LNT, 3'-SL, and 6'-SL for next-generation infant formula applications.

-Nestlé Health Science: Continued strengthening its early-life nutrition research with HMO-enriched formulations designed to improve infant gut health and immune development. Recently expanded premium infant nutrition products integrating multiple HMOs and microbiome-support ingredients for advanced pediatric nutrition.

-Jennewein Biotechnologie GmbH: Advanced microbial fermentation technologies for large-scale HMO production, enhancing the availability of bio-identical oligosaccharides for infant formula manufacturers. Recently focused on expanding 2'-Fucosyllactose (2'-FL) and complex HMO production capabilities for global nutrition brands.

-Inbiose NV: Strengthened precision fermentation platforms for sustainable and cost-efficient HMO manufacturing, supporting broader adoption in functional nutrition products. Recently enhanced scalable bioprocessing technologies for specialty HMOs targeting infant nutrition and gut-health applications.

-DuPont Nutrition & Health: Continued innovation in microbiome-focused nutrition solutions by integrating HMOs into advanced infant and medical nutrition formulations. Recently expanded its science-backed ingredient portfolio supporting digestive health, immune function, and microbiota development in early-life nutrition products.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/human-milk-oligosaccharides-market?ram

Main Drivers and Trends Shaping the Future of the Human Milk Oligosaccharides (HMO) Market
-Infant Nutrition Innovation: Rising demand for premium infant formula enriched with HMOs is driving market growth, as manufacturers aim to replicate the immune and gut health benefits of human breast milk.

-Biotechnology Advancements: Progress in precision fermentation, enzymatic synthesis, and microbial engineering has improved large-scale production efficiency and reduced manufacturing costs for complex HMOs.

-Gut Health Awareness: Increasing consumer focus on microbiome health, digestive wellness, and immunity is expanding HMO applications beyond infant nutrition into adult supplements and functional foods.

-Strategic Industry Expansion: Major nutrition and biotechnology companies are investing in partnerships, R&D collaborations, and regulatory approvals to commercialize novel HMO ingredients globally.

-Clean-Label and Premiumization Trends: Demand for scientifically backed, clean-label nutritional ingredients is encouraging the inclusion of HMOs in pediatric, maternal, and medical nutrition products.

-Market Challenges: High production complexity, stringent regulatory requirements, and expensive purification processes continue to limit widespread adoption and pricing competitiveness.

Regional Insights:
-North America: 34.5% (Largest share, driven by strong adoption of premium infant nutrition products and advanced biotechnology infrastructure).

-Europe: 25.9% (Supported by rising investments in infant health research and strong regulatory approval for HMO-enriched formulas).

-Asia Pacific: 22.4% (Fastest growing region, fueled by increasing birth rates, urbanization, and expanding infant formula demand in China, India, and Japan).

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=human-milk-oligosaccharides-market?ram

Market Segmentation Analysis:
-By Product: 2'-Fucosyllactose (2'FL) Leads Due to Extensive Commercial Adoption
2'-Fucosyllactose (2'FL) dominates the Human Milk Oligosaccharides (HMO) market as it is the most widely studied and commercially used HMO in infant nutrition products.
Lacto-N-neotetraose (LNnT) and Lacto-N-tetraose (LNT) are gaining traction due to their role in gut microbiota development and immune support in infants.
3'-Sialyllactose (3'SL) and 6'-Sialyllactose (6'SL) are increasingly utilized in premium infant formula and cognitive health formulations, while other HMOs are emerging through ongoing biotechnology advancements.

-By Type: Neutral HMOs Dominate Owing to Broad Functional Benefits
Neutral HMOs account for the major market demand because of their strong compatibility with infant formula applications and digestive health benefits.
Acidic HMOs are increasingly adopted for their potential role in brain development, immune modulation, and anti-pathogenic properties.
Other HMO types continue to see research-driven growth as manufacturers expand specialized nutrition portfolios for infants and adults.

-By Application: Infant Formula Remains the Primary Application Area
Infant formula represents the leading application segment due to rising demand for breast milk substitutes enriched with bioactive ingredients that mimic natural human milk.
Dietary supplements are witnessing steady growth as HMOs gain popularity in adult gut health, immunity, and microbiome-support products.
Functional food and beverages are emerging as a promising category, supported by increasing consumer interest in preventive nutrition and advanced health ingredients.

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicated reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.